Chimerix gains on regulatory updates for cancer therapy

Nov. 03, 2022 9:11 AM ETChimerix, Inc. (CMRX)EBSBy: Dulan Lokuwithana, SA News Editor

Quarterly business report concept.

golfcphoto

Chimerix, Inc. (NASDAQ:CMRX), a biotech known for its smallpox therapy Tembexa added ~7% pre-market Thursday after its Q3 2022 results as the company updated on the regulatory path for its investigational cancer therapy ONC201.

The Durham, North Carolina-based company said that with

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.